Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Drug Interactions

Background:

• Morphine is a standard treatment for myocardial infarction pain.
• Morphine use is linked to poorer clinical outcomes.
• A potential interaction with clopidogrel was hypothesized.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic interactions between clopidogrel and morphine.
• To determine if morphine affects clopidogrel's active metabolite levels and antiplatelet effects.

Main Methods:

• A randomized, double-blind, placebo-controlled, cross-over trial was conducted in 24 healthy subjects.
• Subjects received clopidogrel with either placebo or morphine.
• Pharmacokinetics and platelet function were assessed using mass spectrometry and platelet tests.

Main Results:

• Morphine delayed clopidogrel absorption and reduced its active metabolite levels by 34%.
• Morphine delayed maximal platelet inhibition by 2 hours and increased residual platelet aggregation.
• The antiplatelet effects of clopidogrel were diminished, impacting platelet plug formation and closure times.

Conclusions:

• Morphine significantly impairs clopidogrel absorption and reduces its active metabolite levels.
• The antiplatelet effects of clopidogrel are delayed and diminished by morphine administration.
• This interaction may lead to treatment failure in patients relying on clopidogrel, particularly those with specific metabolic profiles.